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Fusion genes involving ZNF384 have recently been identified in B-cell precursor acute lymphoblastic leukemia, and 7 fusion partnershave been reported. We further characterized this type of fusion
gene by whole transcriptome sequencing and/or polymerase chain reac-
tion.  In addition to previously reported genes, we identified BMP2K as
a novel fusion partner for ZNF384.  Including the EP300-ZNF384 that
we reported recently, the total frequency of ZNF384-related fusion
genes was 4.1% in 291 B-cell precursor acute lymphoblastic leukemia
patients enrolled in a single clinical trial, and TCF3-ZNF384 was the
most recurrent, with a frequency of 2.4%. The characteristic
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Introduction
B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) is a heterogeneous disease that can be subdivided
according to primary recurrent genetic abnormalities that
are strongly associated with characteristic biological and
clinical features.1 The detection of these abnormalities can
facilitate diagnosis, risk stratification, and targeted thera-
py.  In approximately two-thirds of pediatric patients with
BCP-ALL, well-characterized genetic abnormalities,
including t(9;22) BCR-ABL1, the rearrangement of MLL at
11q23, t(1;19) TCF3-PBX1, t(17;19) TCF3-HLF, t(12;21)
ETV6-RUNX1, hyperdiploidy, and hypodiploidy, can be
detected by standard genetic analyses.1 In the remaining
BCP-ALL patients, major pathogenic or driver cytogenetic
abnormalities have yet to be clarified, and they are called
"B-others".
Recent studies using advanced analytical approaches
have stratified a variety of subgroups harboring novel
genetic abnormalities. For example, a high-risk subtype in
B-others with a number of fusion genes involving tyrosine
kinases, so-called "Ph-like acute lymphoblastic leukemia
(Ph-like ALL)", was recently discovered.2-3 Besides Ph-like
ALL, other subgroups such as iAMP21, dic(9;20), and
patients with PAX5 abnormalities have also been identi-
fied in B-others.4-7 However, a certain portion of B-others
still remain genetically unclassified.
The zinc-finger protein 384 (ZNF384) gene encodes a
transcription factor that regulates promoters of the extra-
cellular matrix genes8 and is known to be involved in ALL
through fusion with the TET family genes, such as the
Ewing sarcoma breakpoint region 1 gene {EWSR1,
t(12;22)}, TATA box binding protein-associated factor
{TAF15, t(12;17)}, and transcription factor 3 {TCF3 or E2A,
t(12;19)}.9-10 In addition to those previously reported
ZNF384-related fusion genes, we identified EP300-
ZNF384, t(12;22), as a novel recurrent fusion gene with an
incidence of approximately 1% in B-others in a Japanese
cohort.11 The recurrence of EP300-ZNF384 in pediatric
BCP-ALL patients as well as a higher incidence in adoles-
cent and young adult (AYA) BCP-ALL patients was con-
firmed by other groups.12-15 Furthermore, the CREB bind-
ing protein gene {CREBBP, t(12;16)(p13;p13)} has been
most recently identified as another novel fusion partner
for ZNF384.13 So far, however, patients harboring 
ZNF384-related fusion genes have been considered to be a
minor subgroup in pediatric BCP-ALL.8-15 The BCP-ALL
patients with EP300-ZNF384 possess a characteristic
immunophenotype of weak CD10 and aberrant CD13
and/or CD33 expression.11 Although certain immunophe-
notypic features were still observed in some of the
remaining B-others patients, cytogenetic abnormalities in
these cases have yet to be clarified.
In order to further investigate unknown cytogenetic
alterations in the remaining B-others, we employed whole
transcriptome sequencing (WTS).  Herein, we report the
identification of an unexpectedly high incidence of fusion
genes involving ZNF384 genes in BCP-ALL in our cohort.
The immunophenotypic and gene-expression characteris-
tics, accompanying genetic abnormalities as well as the
clinical features of BCP-ALL harboring the ZNF384-related
fusion gene are evaluated and discussed.
Methods
Patient selection
Following previous publication,11 91 ribonucleic acid (RNA)
samples obtained from pediatric BCP-ALL patients classified as B-
others were selected from the Tokyo Children’s Cancer Study
Group (TCCSG) biobank as a discovery cohort for WTS to screen
for unknown fusion genes.  We then extended analysis to another
122 B-others' RNA samples that were available in our biobank as
a validation cohort by employing reverse transcription polymerase
chain reaction (RT-PCR) (detailed information is presented in
Figure 1, Online Supplementary Information andOnline Supplementary
Table S1).
Diagnoses were made on the basis of the morphology and
routine examinations, including the immunophenotype, cytoge-
netic analysis, DNA content analysis, and the RT-PCR detection
of 7 conventional fusion transcripts, as described previously.16
The investigations were approved by the institutional review
boards of all participating institutions.  Informed consent was
obtained from parents or guardians, and informed assent was
obtained from the patients when appropriate, based on their age
and level of understanding.  In the TCCSG study, we first
assigned patients to standard- (SR), intermediate- (IR) and high-
risk (HR) groups based on their age and leukocyte count, and
risk assessment was revised on day 8 based on the response of
the patients to steroid monotherapy.17
Whole transcriptome sequencing and RT-PCR
Using total RNA extracted from the bone marrow or peripheral
blood samples of the patients, WTS was performed and the fusion
transcripts were investigated by employing deFuse, an algorithm
for gene fusion discovery, as described in the Online Supplementary
immunophenotype of weak CD10 and aberrant CD13 and/or CD33 expression was revealed to be a
common feature of the leukemic cells harboring ZNF384-related fusion genes.  The signature gene
expression profile in TCF3-ZNF384-positive patients was enriched in hematopoietic stem cell  features
and related to that of EP300-ZNF384-positive patients, but was significantly distinct from that of
TCF3-PBX1-positive and ZNF384-fusion-negative patients. However, clinical features of TCF3-
ZNF384-positive patients are markedly different from those of EP300-ZNF384-positive patients,
exhibiting higher cell counts and a younger age at presentation. TCF3-ZNF384-positive patients
revealed a significantly poorer steroid response and a higher frequency of relapse, and the additional
activating mutations in RAS signaling pathway genes were detected by whole exome analysis in some
of the cases.  Our observations indicate that ZNF384-related fusion genes consist of a distinct subgroup
of B-cell precursor acute lymphoblastic leukemia with a characteristic immunophenotype, while the
clinical features depend on the functional properties of individual fusion partners.       
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Table 1A. Clinical characteristics of acute lymphoblastic leukemia (ALL) with ZNF384-related fusion genes. 
ID Fusion Age Gender Initial Karyotype Initial Day 8 CNS Current Relapse Salvage FUP Status
partner (years) WBC risk blasts involvement status (date, site) therapy (years)
count (/mL) after 
relapse
Case-1 TCF3 2 F 36,600 46,XX IR 0 CNS1 1st CR 3.5 Alive
Case-2 TCF3 9 M 3,200 46,XY IR 14 CNS1 Relapse 4.7y, BM SCT 7.0 Alive
Case-3 TCF3 3 M 137,260 46,XY HR 639 CNS1 1st CR 6.1 Alive
Case-4 TCF3 2 M 4,000 46,XY SR 0 CNS1 1st CR 6.4 Alive
Case-5 TCF3 1 F 21,100 46,XX IR 1,617 CNS1 1st CR 4.5 Alive
Case-6 TCF3 9 F 2,750 ND IR 1,824 CNS1 1st CR 2.0 Alive
Case-7 TCF3 1 M 49,970 46,XY IR 11,941 CNS1 Relapse 1.6y, BM SCT 2.5 Death
Case-8 TCF3 11 F 1,220 46,XX IR 10 CNS1 1st CR 6.7 Alive
Case-9 TCF3 2 F 150,200 46,XX HR 44,156 CNS1 1st CR 3.6 Alive
Case-10 TCF3 10 F 4,800 46,XX IR 0 CNS1 1st CR 0.7 Alive
Case-11 TCF3 3 F 130,900 46,XX HR 16,816 CNS1 Relapse 3.4y, BM SCT 4.3 Alive
Case-12 TCF3 2 M 49,160 46,XY IR 7,443 CNS1 Relapse 2.9y, BM SCT 3.6 Death
Case-13 TCF3 2 M 27,450 46,XY IR 5,425 CNS1 Relapse 1.6y, BM SCT 2.4 Death
Case-14 TCF3 3 M 105,900 46,XY HR 17,797 CNS1 1st CR 2.4 Alive
Case-15 TCF3 8 M 76,500 46,XY IR 52 CNS2 1st CR 2.3 Alive
Case-16 TAF15 5 M 12,200 46,XY SR 224 CNS1 1st CR 4.7 Alive
Case-17 TAF15 3 M 22,000 46XY IR 537 CNS1 Relapse 5.7y, BM Chemotherapy 6.3 Alive
Case-18 TAF15 8 M 34,100 46,XY IR 2,704 CNS1 1st  CR 1.5 Alive
Case-19 CREBBP 3 F 19,270 47,X,add(X)(p22), SR 3,076 CNS1 1st CR 5.7 Alive
t(12;12)(p13:q13),+21
Case-20 CREBBP 12 F 58,000 46,XX HR 574 CNS1 1st CR 6.4 Alive
Case-21 CREBBP 2 M 26,500 46,XY IR 538 CNS1 Relapse 3.5y, BM Chemotherapy 6.5 Alive
Case-22 BMP2K 5 F 4,100 46,XX SR 17 CNS1 1st CR 10.1 Alive
F: female; M: male; WBC: white blood cell; CNS: central nervous system; FUP: follow up; SR, standard-risk; IR: intermediate-risk; HR: high-risk; CR: complete remission; SCT: stem cell transplan-
tation; BM: bone marrow.
Table 1B. Additional genetic characteristics of acute lymphoblastic leukemia (ALL) with ZNF384-related fusion genes.
Methods Additional genetic mutation
ID Fusion MLPA Whole Whole Samples
partner transcriptome exome obtained MLPA Signaling/adhesion Epigenetic regulator Fusion points
sequencing sequencing at
Case-1 TCF3 ○ Newly diagnosed NP NT Ex11-Ex3
Case-2 TCF3 ○ Newly diagnosed NP NT Ex13-Ex3
Case-3 TCF3 ○ Newly diagnosed NP NT Ex17-Ex7
Case-4 TCF3 ○ ○ Newly diagnosed RB1 del NP Ex13-Ex3
Case-5 TCF3 ○ ○ ○ Newly diagnosed NP ASH1L Ex13-Ex3
Case-6 TCF3 ○ Newly diagnosed NP NP Ex13-Ex3
Case-7 TCF3 ○ ○ ○ Newly diagnosed NP PTPN11 Ex13-Ex3
Case-8 TCF3 Newly diagnosed NT NT Ex17-Ex7
Case-9 TCF3 ○ Newly diagnosed NP NT Ex11-Ex3
Case-10 TCF3 Newly diagnosed NT NT Ex16-Ex2
Case-11 TCF3 ○ Newly diagnosed CDKN2A/2B del NT Ex17-Ex7
Case-12 TCF3 ○ Newly diagnosed NP NT Ex13-Ex3
Case-13 TCF3 ○ ○ ○ 1st relapse NP NRAS EZH2 Ex11-Ex3
Case-14 TCF3 ○ ○ Newly diagnosed NP KRAS, PTPN11 MLL2 Ex13-Ex3
Case-15 TCF3 ○ Newly diagnosed NP ASH1L Ex13-Ex2
Case-16 TAF15 Newly diagnosed NT NT Ex6-Ex3
Case-17 TAF15 ○ ○ ○ Newly diagnosed, NP NP Ex6-Ex3
1st relapse
Case-18 TAF15 ○ Newly diagnosed NP NRAS MLL2 Ex6-Ex3
Case-19 CREBBP ○ ○ Newly diagnosed CDKN2A/2B del NP Ex6-Ex2, Ex5-Ex3
Case-20 CREBB ○ Newly diagnosed NP NT Ex6-Ex3, Ex5-Ex3, 
Ex4-Ex3
Case-21 CREBBP Newly diagnosed NT NT Ex6-Ex3, Ex4-Ex3, 
Ex7-Ex3
Case-22 BMP2K ○ Newly diagnosed NP NP Ex14-Ex3, Ex15-Ex3
MLPA: Multiplex Ligation-dependent Probe Amplification; NP: not particular; NT: not tested;  del: deletion; Ex: exon.
Information. For the confirmation of the whole transcriptome
screening results and screening for additional cases in the valida-
tion cohort, RT-PCR was performed as described previously,18
using the primers listed in the Online Supplementary Table S2, fol-
lowed by Sanger sequencing. The details of the data analyses of
WTS to identify genetic mutations and deletions are also
described in the Online Supplementary Information.
Whole exome sequencing  (WES)
Exome libraries were prepared from 100 ng of genomic DNA
using the Nextera Rapid Capture Exome Kit (Illumina, Inc., San
Diego, CA, USA), and sequenced using SBS v4 reagents with the
HiSeq2500 sequencing system (Illumina).  More than 10 Gb of
sequence was obtained for each library by paired-end sequencing
(126 bp x2). The details of the whole exome data analyses are
described in the Online Supplementary Information.
Microarray and data analyses
The complementary DNAs (cDNAs) were amplified and
labeled using the Ovation® Pico WTA System and Encore™
Biotin Module (NuGEN Technologies Inc., San Carlos, CA, USA),
as instructed by the manufacturer.  The labeled probes were
hybridized to Human Genome U133 Plus 2.0 Arrays (Affymetrix,
Santa Clara, CA, USA). The arrays were analyzed using GeneChip
Operating Software 1.2 (Affymetrix, Santa Clara, CA, USA) and
GeneSpring GX 13.1 software (Agilent Technologies, Santa Clara,
CA, USA), and the details of data analyses, including gene set
enrichment analysis (GSEA), are described in the Online
Supplementary Information.
Statistical analysis
An unpaired t-test with Welch's correction was performed for
the positivity of cell surface antigens.
Mutual univariable analysis of characteristics were conducted
using the Fisher’s exact test or χ2 test for qualitative variables.
Overall survival (OS) and event-free survival (EFS) were estimated
by the Kaplan-Meier method and compared with the log-rank test.
Analyses were performed with the use of Prism software, version
6.0 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
Detection of the fusion genes involving ZNF384 in
pediatric BCP-ALL patients
The 213 selected RNA samples from B-others patients
were analyzed by WTS and/or RT-PCR followed by
Sanger sequencing (Figure 1 and Online Supplementary
Tables S1 and S3).  We identified a total of 15, 3 and 3
patients with TCF3-ZNF384, TAF15-ZNF384 and
CREBBP-ZNF384, respectively.  Three fusion genes were
reported previously.9,10,12-15,19-22 In addition, we identified a
Fusion genes involving ZNF384 in BCP-ALL
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Figure 1.  Flow chart of the analysis of patients. The
respective numbers of patients and cohorts that
were investigated are presented in a hierarchical
fashion.  See also the Online Supplementary
Information and Online Supplementary Table S1.
ALL: acute lymphoblastic leukemia; BCP-ALL: B-cell
precursor ALL; B-others: BCP-ALL without conven-
tional genetic abnormalities; RNA: ribonucleic acid;
RNA-seq-Ex1 and Ex2: RNA-sequencing experiment
1 and 2; RT-PCR-Ex1 and Ex2: reverse transcription
polymerase chain reaction experiment 1 and 2; Ex:
experiment.
S. Hirabayashi et al.
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Figure 2.  Structure of the ZNF384-related fusions.
Structures of fusion proteins and nucleotide
sequences of fusion points of (A) TCF3-ZNF384, (B)
TAF15-ZNF384, (C) CREBBP-ZNF384, and (D)
BMP2K-ZNF384 are presented.  Exon numbers and
boundaries are marked below the protein struc-
tures.  The black arrowhead shows the donor site
fusion point. The white arrowhead shows the accep-
tor site fusion point. Five and four different in-frame
fusions for TCF3-ZNF384 and CREBBP -ZNF384,
respectively, are depicted with the nucleotide
sequence, predicted amino acids, and chro-
matogram.  The patients in whom a particular
fusion isoform was found are indicated on the right.
Ex: exon; TAZ2: transcription adaptor putative zinc
finger; KIX: kinase-inducible domain interacting;
RING: really interesting new gene; PHD: plant home-
odomain; CREB: cyclic adenosine monophosphate
(AMP) response element binding protein; RNA:
ribonucleic acid; ZN: zinc finger; RAN: Ras-related
nuclear proteins; BMP-2: bone morphogenetic pro-
tein 2. 
A
B
C
D
novel ZNF384-related fusion gene, namely BMP2K-
ZNF384 (1 patient).  Although we recently reported 6
patients with EP300-ZNF384,11 another 3 patients with
this fusion gene were further identified in this study
(Figure 1 and Online Supplementary Tables S1 and S4).
Structure of the fusion genes involving ZNF384
The structure and sequences of the fusion points of each
fusion gene as well as a schematic representation of the
predicted fusion proteins are depicted in Figure 2.  In 3 out
of 15 TCF3-ZNF384 patients, the fusion point of ZNF384
was the same as those previously reported, and exon 11 of
TCF3 was fused to exon 3 of ZNF384 (presented in Figure
2A as Type (a)).10 In addition to this known fusion point,
we identified several novel fusion points of this fusion
gene.  Most frequently, for example, exon 13 of TCF3was
fused to exon 3 of ZNF384 with in-frame joining in 7
patients (Figure 2A Type (c)).  The predicted protein from
all of the fusions does not have the principal functional
domains of wild-type TCF3, whereas it retains almost all
of the part of the ZNF384 protein.
The structure and sequences of the fusion point of
TAF15-ZNF384 are depicted in Figure 2B.  Although sever-
al isoforms have been reported in this fusion gene,16 only
one isoform joining exon 6 of TAF15 to exon 3 of ZNF384
was observed in 3 of our patients.
In the case of CREBBP-ZNF384, we identified 5 iso-
forms in 3 patients (Figure 2C).  The exons 4, 5, and 6 of
CREBBP fused in-frame to exon 3 or 2 of ZNF384 (Figure
2C Type (a-d)).  Among all of the fusion points, most func-
tional domains of CREBBP were lacking in the resulting
fusion proteins, while the complete ZNF384 protein was
retained.  In contrast, exon 7 of CREBBPwas fused out-of-
frame to exon 3 of ZNF384 in 1 patient (Figure 2C Type
(e)).
In the case of BMP2K-ZNF384, 2 isoforms were identi-
fied in one patient and nucleotide 2228 (exon 15) and
nucleotide 2117 (exon 14) of BMP2K were fused in-frame
to nucleotide 266 (exon 3) of ZNF384 (Figure 2D, Type (a,
b)), and the predicted protein retained the kinase domain
of BMP2K but lacked the c-terminus portion. The 3
patients with EP300-ZNF384 exhibited identical split
sequences, as we reported previously (data not shown).11
Frequency of ZNF384-related fusion gene-positive
patients
A consecutive series of 333 ALL patients enrolled in the
TCCSG L0416/0616 study11 included 130 B-others
patients and 161 BCP-ALL patients with conventional
genetic abnormalities (291 BCP-ALL patients, Figure 1 and
Online Supplementary Table S1).  Since the majority of these
B-others patients of the L0416/0616 cohort (121 patients,
93.1% of B-others) were studied in the present analysis,
we estimated the frequency of ZNF384-related fusion
genes in childhood ALL based on this cohort.  As we
reported previously, 3 patients with EP300-ZNF384 were
included in the L0416/0616 cohort.11 In the study herein,
we identified another 9 patients with ZNF384-related
fusion genes in this cohort.  Therefore, the frequency of
the total of 12 patients with ZNF384-related fusion genes
in B-others was estimated as 9.2% (4.1% in BCP-ALL,
Figure 1 and Online Supplementary Table S1).  Of those
fusion genes, TCF3-ZNF384 was the most recurrent 
(7 patients), with a frequency of 5.4% in B-others (2.4% in
BCP-ALL).
Immunophenotypic characteristics of BCP-ALL patients
with ZNF384-related fusion genes
As we reported previously, all BCP-ALL patients with
EP300-ZNF384 showed a dull or negative expression of
CD10 and aberrant expression of one or more myeloid
antigens based on immunophenotypic examination.11,13
Fusion genes involving ZNF384 in BCP-ALL
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Table 2. Statistical comparison of clinical characteristics between TCF3-ZNF384-, EP300-ZNF384-, TCF3-PBX1-positive, and ZNF384-related
fusion gene-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
TCF3-ZNF384 EP300-ZNF384 TCF3-PBX1* ZNF384 wild-type*
(N=15) (N=9) (N=17) (N=115)
Sex
Male 8 (53%) 6 (67%) 10 (59%) 63 (55%)
Female 7 (47%) 3 (33%) 7 (41%) 50 (43%)
Age (years)
1-6 10 (67%) 1 (11%) 10 (59%) 71(62%) #1
7-9 3 (20%) 2 (22%) 3 (18%) 14 (12%)
>10 2 (13%) 6 (67%) 4 (24%) 26 (23%)
WBC (x109/L)
<20 5 (33%) 7 (78%) 7 (41%) 80 (70%) #2
20-50 5 (33%) 0 (0%) 6 (35%) 17 (15%)
50-100 1 (7%) 1 (11%) 2 (12%) 5 (4%)
>=100 4 (27%) 1 (11%) 2 (12%) 4 (3%)
Initial risk
SR 1 (7%) 1 (11%) 3 (18%) 42 (37%) #3
IR 10 (67%) 6 (67%) 12 (71%) 53 (46%)
HR 4 (27%) 2 (14%) 2 (12%) 4 (3%)
Treatment response 
PGR 7 (47%) 8 (89%) 14 (82%) 99 (86%) #4
PPR 8 (53%) 1 (11%) 3 (18%) 5 (4%)
Wild-type ZNF384; BCP-ALL without conventional genetic abnormalities as well as ZNF384-related fusions; SR: standard-risk; IR: intermediate-risk; HR: high-risk; WBC: white blood cells; PGR:
predonine good responder; PPR: predonine poor responder. *L0416/0616-registered cases. #1P<0.01 EP300-ZNF384 vs. wild-type ZNF384; P<0.05 EP300-ZNF384 vs. TCF3-ZNF384. #2P<0.05 TCF3-
ZNF384 vs. wild-type ZNF384, TCF3-PBX1 vs. wild-type ZNF384. #3P<0.01 TCF3-ZNF384 vs. wild-type ZNF384; P<0.05 EP300-ZNF384 vs. wild-type ZNF384. #4P<0.01 TCF3-ZNF384 vs. wild-type
ZNF384.
Similar to EP300-ZNF384-positive patients, all of the other
BCP-ALL patients with ZNF384-related fusion genes were
found to have a weak or negative expression of CD10,
ranging from 0.39% to 67.34% (mean: 19.44±18.23%,
Figure 3 and Online Supplementary Table S5), and there was
a significant difference compared with TCF3-PBX1-posi-
tive patients and B-others in which ZNF384-related fusion
genes were not identified (wild-type ZNF384), for the
most part strongly expressing CD10 (mean: 98.66±0.89%,
P<0.001 and mean: 77.71±25.79%, P<0.001, respectively).
In addition, 7 and 17 patients out of 22 patients with
ZNF384-related fusion genes (31.82% and 77.27%,
respectively) exhibited more than 20% expression of
CD13 (mean: 10.70±10.37%) and CD33 (mean:
59.86±34.01%),  significantly distinct from BCP-ALL
patients with TCF3-PBX1 and wild-type ZNF384 express-
ing neither CD13 (mean: 0.26±0.33%, P<0.001 and mean:
2.76±7.9%, P<0.0015, respectively), nor CD33 (mean:
0.59±0.76%, P<0.001 and mean: 6.63±1.72%, P<0.0001,
respectively).
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Figure 3. Immunophenotypic characteristics of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients with ZNF384-related fusion genes. (A) Typical
histograms of CD19, CD10, aberrant myeloid antigens (CD13 and CD33), and CD66c of ZNF384-related fusion gene-positive patients and TCF3-PBX1 patients are
indicated with a positive rate (%).  X-axis, fluorescence intensity; Y-axis, relative cell number. (B) The positivity (percentage) of CD10, 13, and 33 of ZNF384-related
fusion gene-positive BCP-ALL patients (22 cases, excepting EP300-ZNF384) and TCF3-PBX1-positive or wild-type ZNF384 BCP-ALL patients was plotted on a scat-
tergram. The detailed list of positivity for each immunophenotypic marker of the patients is presented in the Online Supplementary Table S5. ZNF384-WT indicates
cases without ZNF384 rearrangement.
A
B
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Figure 4. Characteristics of gene expression profile in TCF3-ZNF384-positive acute lymphoblastic leukemia (ALL). (A) Two-way hierarchical clustering was performed
on filtered microarray probes, those up- or downregulated by 2-fold or more in TCF3-ZNF384- (red, n=10), in comparison with TCF3-PBX1-positive (blue, n=19) ALL.
The results are displayed using a heat map as a dendrogram. (B) Among the genes that exhibited a 2 times higher or lower expression in either TCF3-ZNF384- and
TCF3-PBX1-positive ALL (listed in the Online Supplementary Table S6), the expressions of PAX5 and VPREB genes measured by microarray analysis were plotted on
a scatter diagram, and bars representing the mean±SD are presented. The data of wild-type ZNF384 B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
patients are also presented. (C) Gene set enrichment analysis (GSEA) for curated gene sets of hematopoietic precursors was performed on the differentially
expressed genes between TCF3-ZNF384- (red) and TCF3-PBX1-positive (blue) ALL. Enrichment plots for the hematopoietic stem cells (HSCs), multi-lymphoid progen-
itor (MLP), pro-B cell (Pro-B), early T-cell precursors (ETP), common myeloid progenitors (CMP), granulocyte-monocyte progenitor (GMP), and megakaryocyte-erythroid
progenitor cell (MEP) signatures are presented. Bold lines represent significant enrichments {false discovery rate (FDR) q-value<0.25 and/or nominal (NOM) 
P-value<0.05)}. NES: normalized enrichment score. 
A
C
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Additional genetic abnormalities in ZNF384-related
fusion gene-positive patients
To detect the additional genetic abnormalities in BCP-
ALL with ZNF384-related fusion genes, we performed
multiplex ligation-dependent probe amplification (MLPA)
analysis.  However, MLPA analysis did not reveal that
ZNF384-translocated cases had deleted or amplified
regions in IKZF1, PAX5, ETV6, BTG1, EBF1, CRLF2, and
ERG, and only 2 patients with CDKN2A/B deletion and 1
patient with RB1 deletion out of 15 were detected (Table
1 and Online Supplementary Figure S1).
We preliminarily identified 126 genes as candidates for
recurrent genetic abnormalities occurring in BCP-ALL by
performing somatic point mutation calling from matched
leukemia-normal patient samples based on the results
from WES data from 100 patients with pediatric BCP-
ALL.  We therefore subjected 7 DNA samples of patients
with ZNF384-related fusion genes to WES to filtrate the
126 genes by multi-sample calling for single-nucleotide
variants and short insertions/deletions (Online
Supplementary Information).  Together with the data of
WTS performed for 9 patients (6 patients were subjected
to both WES and WTS), we analyzed them to identify
somatic mutations impacting coding sequences.  As a
consequence, we identified 7 recurrently mutated genes
which had been recognized earlier as abnormalities
involved in leukemia, including NRAS, KRAS, PTPN11,
EZH2, MLL2, and ASH1L (Table 1 and Online
Supplementary Figure S1).  Principally, activating muta-
tions in RAS signaling pathway genes, including NRAS,
KRAS, and PTPN11, were detected in 4 out of 10
ZNF384-translocated patients subjected to WES and/or
WTS.  On the other hand, mutations in B-cell develop-
mental genes, such as PAX5, VPREB1, BTG1, and IKZF1,
were not detected at all in DNA samples from BCP-ALL
with ZNF384-related fusion genes.
Gene expression profile of TCF3-ZNF384-positive
patients
To assess the functional aspects of TCF3-ZNF384, we
performed DNA microarray-based expression profiling.
Hierarchical clustering analysis using the selected gene
probe sets2,3 showed that the major subtypes of BCP-ALL
patients with conventional genetic abnormalities separat-
ed into distinct clusters. Remarkably, ZNF384-related
fusion gene positive patients were located in the same
cluster and clearly separated from those of other conven-
tional genetic subtypes (Online Supplementary Figure S2A)
as well as TCF3-PBX1-positive patients (Online
Supplementary Figure S2B).  The data indicate that the gene
expression profile of TCF3-ZNF384-positive ALL is related
to EP300-ZNF384- and CREBBP-ZNF384-positive ALL,
but not to other conventional genetic subtypes.
Therefore, we proceeded to directly compare the gene
expression of the most frequent TCF3-ZNF384-positive
ALL to that of TCF3-PBX1-positive ALL possessing the
same fusion partner, and with both translocations disrupt-
ing one allele of TCF3 that drives the B-cell differentiation
program.  As shown in the Online Supplementary Figure
S2C and Figure 4A, TCF3-ZNF384-positive patients were
clearly separated in a distinct cluster from TCF3-PBX1-
positive patients by hierarchical clustering, and the differ-
ential expression of 3,698 genes (up: 1,984, down: 1,714,
>2.0) were identified (Online Supplementary Table S6), indi-
cating that two TCF3-translocated subtypes were signifi-
cantly distinct. Interestingly, the B-cell developmental
genes VPREB1, PAX5, and IKZF1-3 were listed as more
highly expressed genes in TCF3-PBX1-positive ALL than
in TCF3-ZNF384-positive ALL (Online Supplementary Table
S6 and Figure 4B).  The transcriptional regulators, such as
BACH2, HIST1H3A, and LEF,1 were also upregulated in
TCF3-PBX1-positive ALL, while GATA3, ERG, NCOR1,
and TOX were upregulated in TCF3-ZNF384-positive
ALL. It is noteworthy that gene set enrichment analysis
revealed a significant enrichment for hematopoietic stem
cell (HSC) signatures in TCF3-ZNF384-positive ALL while
lymphoid features, such as Pro-B cells and early T-cell pre-
cursors (ETP), were more prominent in TCF3-PBX1-posi-
tive ALL (Figure 4C and Online Supplementary Table S7).
The signatures of granulocyte-macrophage progenitor
(GMP)/multi-lymphoid progenitor (MLP) and megakary-
ocyte-erythroid progenitor (MEP) were enriched in TCF3-
ZNF384- and TCF3-PBX1-positive ALL, respectively,
whereas statistical significance was not observed.
The above analyses could just as well detect the lack of
specific TCF3-PBX1 features rather than the common fea-
tures among cases with TCF3-ZNF384. Thus we subse-
quently compared the gene expression of TCF3-ZNF384-
positive ALL to that of wild-type ZNF384. There is the
possibility that the wild-type ZNF384 patients still include
a variety of subgroups harboring novel genetic abnormali-
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Figure 5. Outcomes of patients with ZNF384-related fusion genes. (A) Kaplan-
Meier estimates of event-free survival (EFS) for patients with TCF3-ZNF384,
EP300-ZNF384, and wild-type ZNF384 (log-rank P=0.35 in wild-type ZNF384
vs. TCF3-ZNF384, log-rank P=0.17 in TCF3-ZNF384 vs. EP300-ZNF384. (B)
Overall survival (OS) for the same as above (log-rank P=0.15 in wild-type
ZNF384 vs. TCF3-ZNF384, log-rank P=0.14 in TCF3-ZNF384 vs. EP300-
ZNF384. 
A
B
wild-type
wild-type
ties, and some of them might be related to ZNF384-related
fusion genes by their gene expression.  Indeed, hierarchical
clustering analysis showed that wild-type ZNF384 patients
were not necessarily located in the same cluster, and some
of the cases were dispersed in the clusters of the major sub-
types of BCP-ALL with conventional genetic abnormalities
(Online Supplementary Figure S2D), indicating the hetero-
geneity of wild-type ZNF384 patients.  Furthermore, hier-
archical clustering of ZNF384-related fusion gene positive
patients and wild-type ZNF384 patients indicated that 21
out of 104 wild-type ZNF384 patients located in the same
cluster as ZNF384-related fusion gene positive patients
(Online Supplementary Figure S2E). However, when we
compared TCF3-ZNF384-positive patients and wild-type
ZNF384 patients; excepting those located in the ZNF384-
related fusion gene positive cluster; they were clearly sep-
arated into a distinct cluster by hierarchical clustering
(Online Supplementary Figure S2F), and the differential
expression of 4,515 genes (up: 2,485, down: 2,030, >2.0)
were identified (Online Supplementary Table S8). The B-cell
developmental genes VPREB1 and IKZF1, but not IKZF2 or
IKZF3, were listed as more highly expressed genes in wild-
type ZNF384ALL than in TCF3-ZNF384-positive ALL, and
PAX5 also listed as a relatively highly expressed gene in
wild-type ZNF384 ALL (1.83-fold). The transcriptional reg-
ulators such as BACH2, HIST1H3A, and LEF1 were also
upregulated in wild-type ZNF384 ALL, while GATA3 and
NCOR1, but not ERG and TOX, were upregulated in
TCF3-ZNF384-positive ALL. The gene set enrichment
analysis also revealed an enrichment for HSC, GMP and
MLP signatures in TCF3-ZNF384-positive ALL while Pro-
B, ETP and MEP were more prominent in wild-type
ZNF384ALL, whereas statistical significance was not obvi-
ous (Online Supplementary Figure S2G and Online
Supplementary Table S7). 
Clinical characteristics and outcomes of 
ZNF384-related fusion gene positive patients
The clinical findings and outcomes of BCP-ALL patients
with ZNF384-related fusion genes, other than EP300-
ZNF384, are summarized in Table 1. They were aged
between 1 and 12 years (median: 3) at presentation and
comprised of 12 males and 10 females. Their initial white
blood cell (WBC) counts at presentation ranged from 1,220
to 150,200 (median: 26,975). The analysis of fluids
obtained by lumbar puncture revealed no indication of
central nervous system involvement, with the exception
of one patient with TCF3-ZNF384 (Case-15). Thirteen out
of 22 patients (59.1%) were classified into an IR at the ini-
tial diagnosis, based on an advanced age (4 patients), ele-
vated WBC counts (7 patients), or both (2 patients).  In
addition, 5 patients were classified as HR (22.7%) based
on markedly elevated WBC counts, but not an advanced
age, and thus the SR included only 4 patients (18.2%).
Five out of 15 (33.3%) patients with TCF3-ZNF384 had a
relapse in the bone marrow, all of the patients received
stem-cell transplantation, and 3 patients died.  One patient
each of TAF15- and CREBBP-ZNF384-positive patients
had a relapse in the bone marrow, but both patients were
salvaged by chemotherapy.  It should be emphasized that
no patient died in those with ZNF384-related fusion
genes, other than TCF3-ZNF384.
Importantly, 21 out of 22 patients showed a normal
karyotype on cytogenetic analysis by conventional G-
banding, but the predicted chromosomal translocations,
including t(12;19)(p13;p13) for TCF3-ZNF384,
t(12;17)(p13;q11) for TAF15-ZNF384, t(12;16)(p13;p13) for
CREBBP-ZNF384, and t(4;12)(q21;p13) for BMP2K-
ZNF384were not detected at all (Table 1).  The remaining
patient with CREBBP-ZNF384 (Case-19) showed
47,X,add(X)(p22),t(12;12)(p13:q13),+21 at the initial diag-
nosis, but this was not consistent with the predicted chro-
mosomal translocation.
Since TCF3-ZNF384 was the most recurrent among
ZNF384-related fusion genes detected in the pediatric
BCP-ALL patients, we next compared the characteristics
of TCF3-ZNF384-positive patients with those of wild-
type ZNF384, as well as EP300-ZNF384- and TCF3-PBX1-
positive patients (Table 2).  When compared with wild-
type ZNF384, initial WBC counts and a trend to be classi-
fied in higher risk groups (IR and HR) were significantly
higher in TCF3-ZNF384-positive patients (P<0.05 and
P<0.01, respectively). In contrast, the age at diagnosis was
not significantly different between TCF3-ZNF384-positive
patients and those with wild-type ZNF384. The response
to steroid monotherapy using the cut-off of 1,000/mL for
the blast count in peripheral blood on day 8 was signifi-
cantly poorer in TCF3-ZNF384-positive patients than in
those with wild-type ZNF384 (P<0.01).
As we reported previously, BCP-ALL patients with
EP300-ZNF384 exhibit an advanced age but not signifi-
cantly elevated WBC counts.11 Indeed, compared to the
patients with wild-type ZNF384, those with EP300-
ZNF384 exhibit a significantly older age at presentation
(P<0.01) but not significantly elevated WBC counts
(P=0.37), as presented in Table 2. Therefore, the clinical
features of TCF3-ZNF384-positive patients were clearly
distinct from those of EP300-ZNF384-positive patients. In
the case of TCF3-PBX1-positive ALL, initial WBC counts
were significantly higher than in wild-type ZNF384,
whereas other features were not significantly different.
The 5-year EFS among TCF3-ZNF384-positive patients
and those with wild-type ZNF384were 50.0% and 73.3%
(P=0.35) and the 5-year OS rates were 72.2% and 89.8%
(P=0.15), respectively (Figure 5). Although there was no
statistic significance, the clinical outcomes of TCF3-
ZNF384-positive patients were more unfavorable than in
wild-type ZNF384 patients. In contrast, the 5-year EFS and
the 5-year OS rates of EP300-ZNF384-positive patients
were 83.3% and 100%, respectively, thus being more
favorable than in TCF3-ZNF384-positive and wild-type
ZNF384 patients.
Discussion
We identified a novel fusion gene, BMP2K-ZNF384, in
addition to the previously reported ZNF384-related fusion
genes, including TCF3-, TAF15-, EWSR-, EP300-, 
"CREBBP-", "SYNRG-", and ARID1B-ZNF384, and thus 8
fusion partners for the ZNF384 gene have been identified
so far.9-15,19-22   Considering the current condition, whereby
the frequency of B-others in which specific cytogenetic
abnormalities are not present are markedly decreasing, the
incidence of ZNF384 -related fusion genes in our cohort
was unexpectedly high.  In the literature, 8 ALL patients
with TAF15-ZNF384 have been reported.9,19-21 Similarly, 2
and 3 ALL patients with EWSR1- and TCF3-ZNF384,
respectively, have also been described previously.9-10,20-22
Because 6 out of 13 patients in the literature are adults
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(>21 years), this is the first report on the high frequency of
the recurrence of ZNF384-related fusion genes in child-
hood BCP-ALL in a single nation.  It is possible that the
differences in the outbreak frequency of ZNF384-related
fusion genes in BCP-ALL depending on racial differences
are present, and this type of fusion might be common in
Asians but not in Caucasians. Alternatively, since ZNF384-
related fusion genes are difficult to detect with conven-
tional G-banding, as we presented in this report, ZNF384-
related fusion genes may be found in Caucasians at a sim-
ilar frequency to that in our cohort upon using more sen-
sitive methods such as PCR or fluorescence in situ
hybridization (FISH).
As we presented herein, BCP-ALL patients with
ZNF384-related fusion genes possess a characteristic
immunophenotype. All of the BCP-ALL patients with
ZNF384-related fusion genes, including EP300-ZNF384
that we reported recently, exhibit the dull or negative
expression of CD10 and for the most part express CD13
and/or CD33.  Our observations are consistent with previ-
ous reports because at least 8 among 13 patients with
ZNF384-related fusion genes were CD10-negative and
expressed CD13 and/or CD33 based on the literature.10,20-
22 Since ZNF384 is a commonality in all of these fusion
genes, the aberrant function of the ZNF384 protein may
be responsible for the characteristics of the immunophe-
notype.  The fact that BCP-ALL patients with TCF3-PBX1
are clearly positive for CD10 and have no aberrant
myeloid antigens should support the above notion.  A cor-
relation between the high expression of the GATA3 gene
and CD13/CD33 expression on primary BCP-ALL blasts
with ZNF384-related fusion genes was suggested,13 where-
as the role of ZNF384-fusion proteins in the  expression
characteristics of the antigen remains largely unknown.
BCP-ALL harboring MLL rearrangement also reveals the
negative expression of CD10 and aberrant expression of
myeloid antigens, while such patients frequently express
CD65 and CD15 as aberrant myeloid antigens and are
mainly accompanied by NG2 (7.1) expression.23 Thus, the
presence of ZNF384-related fusion genes should be pre-
dictable, based on the characteristic immunophenotype of
dull or negative CD10 expression accompanied by the
aberrant expression of CD13 and/or CD33.
In contrast to the similarity of the immunophenotypic
characteristics, the clinical features of BCP-ALL with the
ZNF384-related fusion gene are not uniform, and are
thought to depend on the fusion partner gene of ZNF384.
In the TCF3-ZNF384 fusion gene-positive ALL patients,
more than half of the patients were classified into an IR or
HR group because of an elevated WBC count at presenta-
tion, while their onset age was not advanced and there
was no significant difference compared with wild-type
ZNF384 patients.  In addition, approximately half of the
patients exhibited a poor response to prednisolone, and
one-third relapsed, indicating that BCP-ALL patients with
the TCF3-ZNF384 fusion gene include a certain propor-
tion of patients with a poor response to conventional
chemotherapy.  It is noteworthy that stem cell transplan-
tation is effective as salvage therapy for a part of the
relapsed TCF3-ZNF384-positive patients. On the other
hand, we previously reported that EP300-ZNF384 fusion
gene-positive patients exhibited a relatively advanced age
but no significant elevation of the WBC count at presenta-
tion, and showed a good response to prednisolone as well
as a favorable response to conventional chemotherapy.11
Moreover, although one patient has relapsed, the OS rate
of 9 patients with EP300-ZNF384 is currently 100%.
Therefore, the clinical features are significantly different
between TCF3-ZNF384-positive and EP300-ZNF384-pos-
itive patients.
As the fusion genes involving the TCF3 gene, TCF3-
PBX1, TCF3-ZNF384, and TCF3-HLF are known, recent
reports have indicated that the genomic and transcriptom-
ic landscape of TCF3-HLF-positive ALL differs markedly
from TCF3-PBX1-positive ALL, and that TCF3-HLF-posi-
tive ALL exhibited enriched stem cell and myeloid fea-
tures, while lymphoid features were more prominent in
TCF3-PBX1–positive ALL.24 Moreover, the recurrent intra-
genic deletions of PAX5 or VPREB1 as well as activating
mutations in the RAS signaling pathway genes (NRAS,
KRAS, and PTPN11) were common in TCF3-HLF-positive
ALL but rare in TCF3-PBX1-positive ALL.  In the case of
TCF3-ZNF384-positive ALL, abnormalities in such B-cell
developmental genes were also revealed to be rare.
However, the gene expression analysis of TCF3-ZNF384-
positive ALL revealed that PAX5 as well as VPREB1
expressions were lower compared with TCF3-PBX1-posi-
tive and wild-type ZNF384 ALL, and the gene expression
profile of TCF3-ZNF384-positive ALL was markedly dis-
tinct from that of TCF3-PBX1-positive and wild-type
ZNF384 ALL. In addition, the signature of TCF3-ZNF384-
positive ALL exhibited enrichment of the stem cell signa-
ture, similar to that of TCF3-HLF-positive ALL. The low
expression of the gene regulating the pro- to pre-B-cell
transition and expression of a HSC/myeloid-signature
could be features of TCF3-ZNF384-positive ALL. Our data
also indicate the activating mutations in RAS signaling
pathway genes and CDKN2A/B-deletion in a part of the
patients with TCF3-ZNF384. Further studies involving a
large series of patients would be required to elucidate the
prognostic impact of these gene abnormalities in a part of
TCF3-ZNF384-positive patients.
It has been shown that TAF15-, EWSR1-, and TCF3-
ZNF384 induce 3T3 fibroblast transformation.9,25 Since
ZNF384 is a commonality in 8 related fusion genes identi-
fied in BCP-ALL, the aberrant function of the ZNF384 pro-
tein may participate in the development of BCP-ALL,
whereas the precise function of ZNF384 in cellular trans-
formation has yet to be clarified.  Furthermore, the role of
the defects in the function of TET family partner mole-
cules in the development of ALL is still controversial.  On
the other hand, the loss of functions of both EP300 and
CREBBP has been reported to participate in tumorigenesis
by means of epigenetic alterations mediated by reduced
histone acetylation activities.26-29 Recent reports also
described the marked involvement of CREBBP mutations
in the relapse of high hyperdiploid BCP-ALL.27-28
Therefore, both the loss of function in CREBBP or EP300
and the gain of aberrant ZNF384 function could coopera-
tively affect leukemogenesis in ALL harboring these two
fusion genes.  In contrast, the role of BMP2K abnormality
in leukemogenesis is unclear.  Further studies to investi-
gate the molecular basis of ZNF384-related fusion proteins
are required to clarify the precise role of the abnormalities
of ZNF384 as well as its fusion partner genes in leukemo-
genesis.
In conclusion, we clarified that ALL patients harboring
ZNF384-related fusion genes constitute a subgroup with a
characteristic immunophenotype in B-others of a Japanese
cohort with an unexpectedly high incidence, and that the
S. Hirabayashi et al.
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TCF3-ZNF384 fusion gene is the most recurrent.  The clin-
ical features of BCP-ALL with ZNF384-related fusion
genes, however, depend on the functional defect of the
fusion partner gene of ZNF384. Additional studies to elu-
cidate the biological function of the ZNF384-related fusion
protein should shed light on the molecular basis of the
development of BCP-ALL.
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